NCT03405142View on ClinicalTrials.gov

Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

December 4, 2019

Study Completion Date

April 27, 2021

Conditions
Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of the Head and Neck (SCCHN)Head and Neck Cancer
Interventions
DRUG

Panitumumab-IRDye800

Intravenous (IV) panitumumab-IRDye800 (50 mg) 1 to 5 days prior to surgery (lymphadenectomy). Panitumumab dose is \< 1/12 of the therapeutic dose.

DRUG

Lymphoseek

Local, peri-tomoral injection with 2 mCi Lymphoseek (99mTc Tilmanocept) (as 4 x 0.1 mL injections of Lymphoseek solution

Trial Locations (1)

94304

Stanford University, School of Medicine, Palo Alto

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Eben Rosenthal

OTHER

NCT03405142 - Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer | Biotech Hunter | Biotech Hunter